Pfizer Pregabalin NDA Will Include Anxiety Use; Filing Date Pushed To 2002
Executive Summary
Pfizer's updated pregabalin NDA filing schedule calls for three initial indications - add-on epilepsy, neuropathic pain and generalized anxiety disorder - to be submitted in 2002
You may also be interested in...
Pfizer/Pharmacia Sales Force Debuts In June; Inspra Launch Delayed
The restructured Pfizer/Pharmacia sales force will begin operations in June
Pfizer/Pharmacia Sales Force Debuts In June; Inspra Launch Delayed
The restructured Pfizer/Pharmacia sales force will begin operations in June
Pfizer pregabalin NDA
Pfizer will submit pregabalin NDA in the U.S. following March 2003 European submission, company says Sept. 6. Filing will include FDA-requested toxicological mechanistic studies. Pfizer had hoped to submit the application in 2002. The delay is the second for the Neurontin follow-on; the NDA was delayed in late 2001 while Pfizer added carcinogenicity data and studies supporting a generalized anxiety disorder indication (1"The Pink Sheet" Dec. 24, 2001, p. 18). Pfizer is seeking approval for add-on epilepsy, neuropathic pain and GAD...